Skip to main content
36°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Repare Therapeutics Inc
(NQ:
RPTX
)
3.580
+0.230 (+6.87%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Repare Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)
February 16, 2024
From
Kirby McInerney LLP
Via
Business Wire
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
February 15, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Roche Terminates Cancer Drug Pact With Repare Therapeutics, Its Second Walkout Within A Month
February 13, 2024
Repare Therapeutics regains global rights to camonsertib (RP-3500) after terminating collaboration with Roche. $40M milestone achieved.
Via
Benzinga
Repare Therapeutics to Regain Global Rights to Camonsertib
February 12, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Recap: Repare Therapeutics Q3 Earnings
November 09, 2023
Via
Benzinga
Wall Street Thinks This Cathie Wood Stock Could Jump by 187%
August 16, 2023
This small-cap biotech stock holds enormous growth potential.
Via
The Motley Fool
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
January 25, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
January 08, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
January 04, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Analyst Expectations for Repare Therapeutics's Future
June 09, 2023
Via
Benzinga
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
December 29, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor
November 15, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
These Biotech Stocks Could Double Your Money, According To Analysts
November 09, 2023
Via
Benzinga
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
November 09, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast
November 07, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
$2.8M Bet On Repare Therapeutics? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
November 06, 2023
The Dow Jones closed higher by over 200 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 06, 2023
Via
Benzinga
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
November 06, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib
October 13, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday's Mid-Day Session
October 09, 2023
Gainers ParaZero Technologies Ltd. (NASDAQ: PRZO) shares jumped 106% to $2.3901 after the company announced an Australian regulator approved first commercial drone flights in populated areas and near...
Via
Benzinga
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 03, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 19, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
September 06, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
August 10, 2023
Via
Benzinga
Repare Therapeutics Inc. (NASDAQ: RPTX) Near the Top of Equities by Percentage Gain on 8/10
August 10, 2023
Via
Investor Brand Network
Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
August 09, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 9, 2023
June 09, 2023
Via
Benzinga
Repare Therapeutics Releases Early Anticancer Activity From Its Monotherapy, Combination Trials
June 08, 2023
Repare Therapeutics Inc (NASDAQ: RPTX) reported initial proof of concept monotherapy data from its Phase 1 MYTHIC trial evaluating lunresertib (RP-6306) in molecularly selected
Via
Benzinga
Repare Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
June 08, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials
June 07, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.